Latest posts

News
2022

WeRide reaches 10 million kilometers of autonomous driving

(01/17/2022) WeRide, a global leading L4 autonomous driving technology company, announces the breakthrough of reaching 10 million kilometers of autonomous driving on public roads, among which 2.5 million kilometers are in fully driverless mode.

News
2022

The 10 most innovative companies in data science for 2022

(3/8/2022) Explore the full 2022 list of Fast Company’s Most Innovative Companies, 528 organizations whose efforts are reshaping their businesses, industries, and the broader culture. We’ve selected the firms making the biggest impact with their initiatives across 52 categories, including the most innovative media, design, and AI companies.

News
2022

Singleron Acquires Proteona

(3/7/2022) Singleron Biotechnologies, a leading Chinese genomics company that develops groundbreaking single-cell multi-omics platform technologies and promotes their clinical translations, today announced the acquisition of Proteona Pte. Ltd., a Singapore-based precision medicine company offering single-cell biomarker discovery services to translational and clinical researchers across the globe. By acquiring Proteona's existing network throughout greater Asia, Europe, the US and Canada, the acquisition strengthens Singleron's position outside China and provides Singleron access to Proteona's technologies for single-cell multi-omic analysis and expertise in generating insights for the Biopharmaceutical market.

Articles
2021

AVCJ: Venture capital investors in China are turning their minds and manpower to the country’s nascent enterprise software opportunity, but the evolution curve is unlikely to be an exact match of the US

(11/20/2019) To many industry participants, software-as-a-service (SaaS) – specifically the migration of on- premises software to cloud-based solutions – is the biggest opportunity on the dark side. China’s enterprise-level SaaS market was worth RMB24.3 billion in 2018, a 48% year-on-year increase on 2017. IResearch Consulting projects it will reach RMB65.4 billion by 2021.

Articles
2021

华创资本卢汉杰：手术机器人和Digital Surgery的投资研究和实践

手术机器人技术壁垒高、研发资源投入大，市场规模正快速增长。为了使手术机器人提供更多的临床价值，产学投研界需要付出相当多的努力，随之而来的市场空间也非常巨大。相比于手术机器人，我们认为Digital Surgery更相对准确地反应了手术机器人现在的含义。手术机器人是一个非常生物医学工程驱动的行业，从投资人的角度看，造手术机器人的难度其实并不亚于造车，符合临床需求是其实践门槛。如果脱离临床价值，同时Workflow Efficiency设计的不好、成本控制不到位，那整个投资模型就不成立。华创资本生命科学组投资人卢汉杰撰文，分享了华创资本对于整个手术机器人或者Digital Surgery领域的一些认知，以及我们的投资逻辑和投资实践。